Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.46 |
| ▸ | NNMT | P40261 | 1/20 | 0.43 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.39 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31627890 | 0.81 | JAK2 (0.46) | JAK2JAK1TYK2NNMTPIK3CA | |
| SCHEMBL31627922 | 0.79 | JAK2 (0.42) | JAK2JAK1TYK2RAB9ACYP3A4 | |
| SCHEMBL31627634 | 0.78 | JAK2 (0.44) | JAK2JAK1TYK2NNMTRAB9A | |
| SCHEMBL19200589 | 0.77 | AAK1 (0.43) | JAK2JAK1TYK2CYP3A4AAK1 | |
| SCHEMBL31627729 | 0.77 | JAK2 (0.43) | JAK2JAK1TYK2NNMTRAB9A | |
| SCHEMBL31627881 | 0.76 | CHEK1 (0.46) | JAK2JAK1TYK2CHEK1RAB9A | |
| SCHEMBL27473173 | 0.73 | PIK3CA (0.53) | JAK2JAK1TYK2PIK3CARAB9A | |
| SCHEMBL21508686 | 0.73 | L3MBTL1 (0.50) | JAK2JAK1TYK2NPC1AAK1 | |
| SCHEMBL30962579 | 0.72 | PIK3CA (0.52) | JAK2JAK1TYK2PIK3CARAB9A | |
| SCHEMBL32667105 | 0.72 | MAP4K1 (0.42) | JAK2JAK1TYK2PIK3CACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236609-A1 | VPS34 INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2025-07-24 | — | — | US | disclosed |
| WO-2025129019-A1 | VPS34 INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236609-A1 | VPS34 INHIBITORS AND METHODS OF USE THEREOF | VPS35, VPS28, VPS26B | JAK2 1725/4885JAK1 690/4885TYK2 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.